
Oncology NEWS International
- Oncology NEWS International Vol 6 No 8
- Volume 6
- Issue 8
Hopkins' Stem Cell Selection Patents Upheld
WILMINGTON, Del--A Federal judge has ordered CellPro, Inc. to pay Johns Hopkins University, Becton Dickinson & Company, and Baxter Healthcare Corp. $7 million in damages for its willful infringement of patents involving stem cell selection technology.
WILMINGTON, Del--A Federal judge has ordered CellPro, Inc. to pay JohnsHopkins University, Becton Dickinson & Company, and Baxter HealthcareCorp. $7 million in damages for its willful infringement of patents involvingstem cell selection technology.
The judge also ordered an injunction against CellPro's patent-infringingstem cell selection system (Ceprate Stem Cell Concentration System andCeprate LC34 Laboratory Cell Separation System). This injunction will bedelayed in this country until an alternative system, licensed under thepatents, is approved by the FDA.
Johns Hopkins and its licensees requested the delay to ensure that transplantpatients have uninterrupted access to stem cell selection technology. Baxter'sIsolex 300 Magnetic Cell Separator System, already in widespread use inclinical trials, is currently under FDA review.
Articles in this issue
almost 29 years ago
Two-Step Approach Urged to Avoid High Tech, Wild Deathalmost 29 years ago
Health Insurance Premiums Tax Proposedalmost 29 years ago
ODAC Votes Yes on Taxol for Kaposi's Sarcomaalmost 29 years ago
Five Principles Help Resolve Ethical Dilemmas in Carealmost 29 years ago
Ovarian Cancer Survivors Form National Coalitionalmost 29 years ago
Photodynamic Therapy Used in Nonmelanoma Skin Canceralmost 29 years ago
Increased Numbers of Nevi Can Predict Risk of Melanomaalmost 29 years ago
With Genetic Tests, Informed Consent Enters Psychosocial Realmalmost 29 years ago
Cryoablation May Have Limited Role in Prostate Cancer Treatmentalmost 29 years ago
Americans Not Convinced of Value of Watchful WaitingRelated Content




109 Extended Adjuvant Neratinib in HER2+/HR+ Early Breast Cancer in Clinical Routine: Final Results from the Multi-national, Prospective, Observational Study ELEANOR



















































